Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis
Yaoyao Jing, Donghui Xing, Ao Jia, Shanshan Xu, Yixin Zhai, Xiaofang Wang, Bing Ang, Zhigang Zhao · 2026
Read Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis by Yaoyao Jing, Donghui Xing, Ao Jia, Shanshan Xu, Yixin Zhai, Xiaofang Wang, Bing Ang, Zhigang Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473156.txt.
Description
Jing and colleagues compared in 2026 the treatment options for advanced lung cancer that grows again after targeted EGFR drugs stop working. At that point plain chemotherapy helps little, and many add-on regimens compete with differing gains and harms. The team pooled randomized trials and ranked eight strategies by both benefit and safety.
Eleven trials with 3,606 patients fed the analysis. Several add-ons slowed cancer growth more than chemotherapy alone, and two also lengthened life: a drug-conjugate called sacituzumab tirumotecan and chemotherapy paired with ivonescimab. Antibody-based pairs worked well too but raised the rate of severe side effects. When benefit and harm were weighed together, the same three strategies kept finishing on top.
Catalog record
| CREATOR | Yaoyao Jing, Donghui Xing, Ao Jia, Shanshan Xu, Yixin Zhai, Xiaofang Wang, Bing Ang, Zhigang Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |